Tango Therapeutics (TNGX) Operating Leases (2020 - 2025)
Historic Operating Leases for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $31.7 million.
- Tango Therapeutics' Operating Leases fell 892.33% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year decrease of 892.33%. This contributed to the annual value of $34.0 million for FY2024, which is 759.81% down from last year.
- Per Tango Therapeutics' latest filing, its Operating Leases stood at $31.7 million for Q3 2025, which was down 892.33% from $32.5 million recorded in Q2 2025.
- Tango Therapeutics' 5-year Operating Leases high stood at $39.9 million for Q3 2022, and its period low was $6.1 million during Q3 2021.
- Over the past 5 years, Tango Therapeutics' median Operating Leases value was $35.8 million (recorded in 2024), while the average stood at $33.9 million.
- Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 55605.19% in 2022, then tumbled by 892.33% in 2025.
- Quarter analysis of 5 years shows Tango Therapeutics' Operating Leases stood at $6.1 million in 2021, then skyrocketed by 546.43% to $39.4 million in 2022, then fell by 6.41% to $36.8 million in 2023, then decreased by 7.6% to $34.0 million in 2024, then dropped by 6.99% to $31.7 million in 2025.
- Its Operating Leases was $31.7 million in Q3 2025, compared to $32.5 million in Q2 2025 and $34.1 million in Q1 2025.